PMID- 18754882
OWN - NLM
STAT- MEDLINE
DCOM- 20081006
LR  - 20141120
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 99
IP  - 8
DP  - 2008 Aug
TI  - Humoral immune responses against tumor-associated antigen OVA66 originally 
      defined by serological analysis of recombinant cDNA expression libraries and its 
      potentiality in cellular immunity.
PG  - 1670-8
LID - 10.1111/j.1349-7006.2008.00860.x [doi]
AB  - Immunotherapy for cancer relies on the identification of tumor antigens and 
      efficacy of antitumor immune responses. Serological analysis of recombinant cDNA 
      libraries (SEREX), which is based on the spontaneous humoral responses against 
      potential tumor antigens, has provided a novel strategy for searching novel 
      tumor-associated candidates. Through SEREX analysis, we have identified 24 
      distinct gene clones by immunoscreening of a cDNA library derived from an ovarian 
      cancer patient. Among these genes, a novel gene, OVA66, was found to be expressed 
      significantly higher in carcinoma samples from cancer patients than in normal 
      controls. Comparing humoral responses to OVA66 between tumor patients and healthy 
      donors, it has been shown that the IgG level against OVA66 was significantly 
      elevated in the serum of cancer patients from different histological types of 
      cancer. To determine whether SEREX-defined OVA66 can trigger promising cytotoxic 
      T lymphocyte (CTL) responses, human leukocyte antigen (HLA)-A*0201-restricted 
      T-cell epitopes were predicted through a computational algorithm. Of four 
      predicted peptides, p306-314 (L235) possesses the ability to induce efficient 
      peripheral blood lymphocyte (PBL)-derived CTL responses capable of specifically 
      recognizing peptide-pulsed T2 cells and lysing carcinoma cell lines expressing 
      both HLA-A2 and OVA66 as determined by cytotoxicity and enzyme-linked immunospot 
      assay (ELISPOT). Taken together, our results demonstrate that the SEREX-defined 
      tumor-associated antigen OVA66 can elicit humoral immunity and may also serve as 
      a potential candidate for T-cell-based immunotherapy for cancer.
FAU - Jin, Shu
AU  - Jin S
AD  - Shanghai Institute of Immunology, Shanghai Jiaotong University School of 
      Medicine, Shanghai, PR of China.
FAU - Wang, Ying
AU  - Wang Y
FAU - Zhang, Yong
AU  - Zhang Y
FAU - Zhang, Hui-Zhen
AU  - Zhang HZ
FAU - Wang, Shu-Jun
AU  - Wang SJ
FAU - Tang, Jun-Qiao
AU  - Tang JQ
FAU - Chen, Hui-Juan
AU  - Chen HJ
FAU - Ge, Hai-Liang
AU  - Ge HL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA, Recombinant)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Amino Acid Sequence
MH  - Antibody Formation
MH  - *Antigens, Neoplasm
MH  - Case-Control Studies
MH  - China
MH  - *DNA, Recombinant
MH  - Female
MH  - Gene Expression
MH  - Gene Library
MH  - Humans
MH  - Immunity, Cellular
MH  - Immunoglobulin G/blood
MH  - Immunotherapy/methods
MH  - In Vitro Techniques
MH  - Molecular Sequence Data
MH  - Ovarian Neoplasms/*immunology
MH  - T-Lymphocytes, Cytotoxic
EDAT- 2008/08/30 09:00
MHDA- 2008/10/07 09:00
CRDT- 2008/08/30 09:00
PHST- 2008/08/30 09:00 [pubmed]
PHST- 2008/10/07 09:00 [medline]
PHST- 2008/08/30 09:00 [entrez]
AID - CAS860 [pii]
AID - 10.1111/j.1349-7006.2008.00860.x [doi]
PST - ppublish
SO  - Cancer Sci. 2008 Aug;99(8):1670-8. doi: 10.1111/j.1349-7006.2008.00860.x.